NFE2L2 and non-small cell lung carcinoma: In a cohort of 330 patients with advanced KRAS-mutant NSCLC, KEAP1/NFE2L2 alterations were associated with shorter overall survival (HR 1.96; 95% CI, 1.33–2.92; p ≤ 0.001), reduced duration of response to platinum-based chemotherapy (HR 1.64; 95% CI, 1.04–2.59; p = 0.03), and decreased survival after initiation of PD-(L)1 inhibition (HR 3.54; 95% CI, 1.55–8.11; p = 0.003 [75].